Product image of Levosimendan Kabi (Levosimendan) supplied by GNH India

Levosimendan Kabi

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Kabi (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Kabi, is a calcium sensitizer / inodilator presented as an injectable solution for intravenous infusion use. It treats acute decompensated heart failure in adult patients.
GNH India supplies Levosimendan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Fresenius Kabi Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levosimendan acts on the cardiovascular system to improve cardiac performance in heart‑failure states.

  • Acute decompensated heart failure: enhances cardiac output and relieves symptoms of congestion.
  • Cardiogenic shock (off‑label): provides hemodynamic support when conventional therapy is insufficient.
  • Heart failure with reduced ejection fraction: improves contractility and reduces afterload, aiding functional recovery.

How It Works

  • Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac preload and afterload.

Side Effects

Levosimendan may cause a range of adverse reactions during and after infusion.

Common Side Effects

  • Hypotension: drop in blood pressure, especially during rapid infusion.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Tachycardia: increased heart rate.
  • Atrial fibrillation: new‑onset irregular rhythm.

Serious or Rare Side Effects

  • Severe hypotension: may require vasopressor support.
  • Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
  • Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
  • Anaphylactic reaction: rare hypersensitivity requiring immediate intervention.
  • Hepatic dysfunction: elevated liver enzymes in susceptible patients.

Precautions & Warnings

Levosimendan requires careful monitoring and patient selection to minimise risks.

  • Cardiovascular monitoring: continuously observe blood pressure and heart rate during infusion.
  • Renal impairment: adjust infusion rate and monitor renal function closely.
  • Electrolyte disturbances: correct hypokalemia or hypomagnesemia before administration.
  • Concomitant vasodilators: use with caution due to additive hypotensive effect.
  • Beta‑blockers and calcium channel blockers: may blunt therapeutic response; monitor closely.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

  • Sodium nitroprusside: additive vasodilation may cause severe hypotension.
  • Beta‑blockers: may reduce inotropic effect of levosimendan.
  • Calcium channel blockers: increase risk of arrhythmias.

Moderate Interactions (Monitor Closely)

  • Diuretics: may potentiate hypotension; monitor volume status.
  • ACE inhibitors/ARBs: combined effect on blood pressure requires observation.
  • Other inotropes (dobutamine, milrinone): overlapping mechanisms may necessitate dose adjustment.

Frequently Asked Questions

Levosimendan Kabi is indicated for the treatment of acute decompensated heart failure and may be used off‑label in cardiogenic shock. It improves cardiac contractility and reduces vascular resistance, helping to restore adequate circulation in critically ill patients.

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances myocardial contractility without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that lowers preload and afterload.

The dosing regimen for Levosimendan Kabi is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber sets the infusion rate, duration, and any necessary adjustments during therapy.

Safety data for levosimendan during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Unlike traditional inotropes such as dobutamine, levosimendan enhances contractility by calcium sensitisation rather than increasing intracellular calcium, which may reduce the risk of calcium‑overload arrhythmias. Compared with phosphodiesterase inhibitors like milrinone, it also provides vasodilation through potassium‑channel activation, offering a broader haemodynamic profile.

Levosimendan Kabi must be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Levosimendan Kabi is given as an intravenous infusion. After reconstitution, the solution is administered through a dedicated IV line, typically starting with a loading dose followed by a continuous infusion, with vital signs monitored throughout the procedure.

The most critical risks include severe hypotension, myocardial ischemia, and life‑threatening ventricular arrhythmias. Early recognition of these events and prompt intervention, such as vasopressor support or anti‑arrhythmic therapy, are essential during treatment.

Levosimendan is contraindicated in patients with uncontrolled severe hypotension, obstructive cardiomyopathy, recent acute myocardial infarction, or known hypersensitivity to the drug. Caution is also advised in severe renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT